Journal article · 2026 · Open access

Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

Tamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura, Najia Karim Ghanchi, Megha Rajasekhar, Bipin Adhikari, Benedikt Ley, Samuel Alemu Bamboro, Fareeha Abdul Jabbar, Nurfadhilah Hasibuan, Tedla Teferi Tego, Shane Zehra and 51 more

The Lancet Infectious Diseases, 26(6), 614–626 · Published 11 February 2026 · DOI 10.1016/s1473-3099(25)00729-7

Open full textCite this paper

In brief

“Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial” is a 2026 journal article by Tamiru Shibiru Degaga and 62 co-authors, published in The Lancet Infectious Diseases. OpenAlex counts 23 citations as of 17 November 2026. It is open access under a CC BY licence: the full text is free to read at The Lancet Infectious Diseases.

Citations
23
Most cited in
2026 (22)
Field-weighted impact
89.60
References
33
Authors
63

Abstract

BACKGROUND: Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmodium vivax infections, but there are few data on their comparative effectiveness when provided unsupervised. We aimed to assess the effectiveness and safety of these new treatment options. METHODS: We conducted a multicentre, open-label, randomised, controlled, superiority trial in Ethiopia, Pakistan, Indonesia, and Cambodia. Adult patients (aged ≥18 years, or aged ≥16 years in Indonesia) with uncomplicated P vivax infection and glucose-6-phosphate dehydrogenase (G6PD) activity of 70% or greater were eligible for enrolment. Patients were treated with blood schizonticidal drugs (chloroquine in Ethiopia and Pakistan, dihydroartemisinin-piperaquine in Indonesia, and artesunate-pyronaridine in Cambodia) and randomly assigned (1:1:1) by an independent statistician using randomly permuted blocks of varying sizes to receive 7 days of unsupervised high-dose primaquine (total dose 7 mg/kg), single-dose tafenoquine (300 mg), or 14 days of low-dose primaquine (total dose 3·5 mg/kg). Randomisation was stratified by site. The primary endpoint, assessed in the modified intention-to-treat population (ie, patients who received allocated treatment, and were not lost to follow-up before day 15), was the cumulative incidence of any P vivax parasitaemia within 6 months compared between the primaquine groups, with the comparison of cumulative incidence between the tafenoquine group and the 14-day low-dose primaquine group a secondary endpoint. Key safety outcomes included the numbers of adverse and serious adverse events, including the number of gastrointestinal symptoms as well as the risk of anaemia. Safety outcomes were assessed in all patients who received any doses of study drug. The study is registered at ClinicalTrials.gov, NCT04411836, and is complete. FINDINGS: Between April 25, 2021 and Sept 13, 2024, 4850 patients were screened for eligibility, of whom 960 patients (672 [70·0%] were male and 288 [30·0%] were female) were enrolled and randomly assigned (320 patients per group). The modified intention-to-treat population of 295 patients allocated to the 7-day high-dose primaquine group, 305 patients allocated to the tafenoquine group, and 301 patients allocated to the 14-day low-dose primaquine group were considered at risk of P vivax recurrence from day 15 onwards. The cumulative incidence of P vivax recurrence at 6 months was 13·0% (97·55% CI 9·0-18·5) in the 7-day high-dose primaquine group and 18·5% (13·8-24·6) in the 14-day low-dose primaquine group (hazard ratio [HR] 0·66 [97·55% CI 0·40-1·09], p=0·063). The corresponding incidence in the tafenoquine group was 12·6% (97·55% CI 8·8-18·0), with an HR of 0·64 (97·55% CI 0·39-1·05, p=0·041) compared with the 14-day low-dose primaquine group. Of the adverse events occurring before day 42, 24 (42·9%) of…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Degaga, T. S., Pasaribu, A. P., Tripura, R., Ghanchi, N. K., Rajasekhar, M., Adhikari, B., Ley, B., Bamboro, S. A., Jabbar, F. A., Hasibuan, N., Tego, T. T., Zehra, S., Qurashi, B., Mnjala, H., Lee, G., Li, P., Kazi, A. M., Safitri, W., Yulita, Y., . . . Thriemer, K. (2026). Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial. The Lancet Infectious Diseases, 26(6), 614–626. https://doi.org/10.1016/s1473-3099(25)00729-7

MLA 9

Degaga, Tamiru Shibiru, et al. “Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.” The Lancet Infectious Diseases, vol. 26, no. 6, 2026, pp. 614–626. https://doi.org/10.1016/s1473-3099(25)00729-7.

Chicago

Degaga, Tamiru Shibiru, Ayodhia Pitaloka Pasaribu, Rupam Tripura, Najia Karim Ghanchi, Megha Rajasekhar, Bipin Adhikari, Benedikt Ley, et al. 2026. “Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.” The Lancet Infectious Diseases 26 (6): 614–626. https://doi.org/10.1016/s1473-3099(25)00729-7.

Harvard

Degaga, T. S. et al. (2026) ‘Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial’, The Lancet Infectious Diseases, 26(6), pp. 614–626. doi:10.1016/s1473-3099(25)00729-7.

IEEE

T. S. Degaga et al., “Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial,” The Lancet Infectious Diseases, vol. 26, no. 6, pp. 614–626, 2026, doi: 10.1016/s1473-3099(25)00729-7.

BibTeX

@article{degaga2026effectiveness,
  title     = {{Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial}},
  author    = {Degaga, Tamiru Shibiru and Pasaribu, Ayodhia Pitaloka and Tripura, Rupam and Ghanchi, Najia Karim and Rajasekhar, Megha and Adhikari, Bipin and Ley, Benedikt and Bamboro, Samuel Alemu and Jabbar, Fareeha Abdul and Hasibuan, Nurfadhilah and Tego, Tedla Teferi and Zehra, Shane and Qurashi, Bushra and Mnjala, Hellen and Lee, Grant and Li, Peixuan and Kazi, Abdul Momin and Safitri, Widaya and Yulita, Yulita and Siagian, Dedi Sahat Parningotan and Syahputra, Deni and Hadi, Halik and Muhammad, Taj and Ibrahim, Amna and Syed, Nasreen and Dost, Khuda and Puspitrasari, Agatha Mia and Kariodimedjo, Pinkan and Rai, Anjana and Rumaseb, Angela and others},
  journal   = {The Lancet Infectious Diseases},
  year      = {2026},
  volume    = {26},
  number    = {6},
  pages     = {614--626},
  doi       = {10.1016/s1473-3099(25)00729-7},
  url       = {https://doi.org/10.1016/s1473-3099(25)00729-7}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control

  • vivax malaria
  • primaquine
  • tafenoquine
  • relapse prevention
  • glucose-6-phosphate dehydrogenase
  • anemia
  • gastrointestinal adverse effects
  • dihydroartemisinin-piperaquine

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Degaga, T. S., Pasaribu, A. P., Tripura, R., Ghanchi, N. K., Rajasekhar, M., Adhikari, B., Ley, B., Bamboro, S. A., Jabbar, F. A., Hasibuan, N., Tego, T. T., Zehra, S., Qurashi, B., Mnjala, H., Lee, G., Li, P., Kazi, A. M., Safitri, W., Yulita, Y., . . . Thriemer, K. (2026). Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial. The Lancet Infectious Diseases, 26(6), 614–626. https://doi.org/10.1016/s1473-3099(25)00729-7

How many times has this paper been cited?

23 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Infectious Diseases: sign in and open the full text from this page.

Who wrote this paper?

Tamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura, Najia Karim Ghanchi, Megha Rajasekhar, Bipin Adhikari, Benedikt Ley, Samuel Alemu Bamboro, Fareeha Abdul Jabbar, Nurfadhilah Hasibuan, Tedla Teferi Tego, Shane Zehra and 51 more.

What is the DOI of this paper?

10.1016/s1473-3099(25)00729-7, permanently at https://doi.org/10.1016/s1473-3099(25)00729-7. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.